Pharmaceuticals
Novo Nordisk achieved a critical milestone in the final days of 2025 when the FDA approved the first oral GLP-1 medication for weight loss, positioning the Danish pharmaceutical giant for what analysts describe as a "must-win" battle in the increasingly competitive obesity treatment market. The approval of Wegovy
Biotechnology
Omeros Corporation launches YARTEMLEA, the first and only FDA-approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), offering hope to thousands of patients facing a condition with mortality rates exceeding 90% in severe cases.
Biotechnology
Insilico Medicine completes Hong Kong's largest biotech IPO of 2025, raising $292 million and becoming the first AI-driven biotech company to list on the Hong Kong Stock Exchange's Main Board.
Biotechnology
A groundbreaking study published in Science has identified a rare genetic variant that acts as a natural shield against blood cancers, offering a 20% reduction in risk for those fortunate enough to carry it. The discovery not only illuminates why some people remain resilient against age-related blood malignancies but also
Biotechnology
Atara Biotherapeutics faces a critical FDA decision on January 10, 2026, for Tabelecleucel, which could become the first approved treatment for EBV+ PTLD, a rare cancer affecting transplant patients.
Pharmaceuticals
Swedish Orphan Biovitrum (Sobi) acquires Arthrosi Therapeutics for up to $1.5 billion, positioning itself as a major player in next-generation gout treatment with pozdeutinurad.
Biotechnology
BioAtla's $40 million partnership with GATC Health to advance ozuriftamab vedotin into Phase 3 trials represents a sophisticated evolution in biotech financing and precision cancer therapeutics, with implications for both oncology and longevity research.
Biotechnology
T-MAXIMUM Pharmaceutical's MT027 receives FDA IND clearance for Phase II trials, marking a potential breakthrough in allogeneic CAR-T therapy for solid tumors and glioblastoma treatment.
Pharmaceuticals
January 2026 marks a pivotal month for pharmaceutical innovation with five critical FDA decisions that could transform patient care across rare diseases, oncology, and ophthalmology.
Biotechnology
The final days of 2025 delivered a devastating blow to Ultragenyx Pharmaceutical as the company lost over $1 billion in market value following the failure of its bone disease therapy setrusumab in two pivotal Phase III trials. The December 29 announcement that the drug failed to reduce fracture rates in
Pharmaceuticals
Vanda Pharmaceuticals surged 25.46% following FDA's Breakthrough Therapy Designation for VVX-001 and a strategic European partnership, signaling major progress in psychedelic-assisted therapy for treatment-resistant depression.
Biotechnology
AbbVie kicked off 2026 with a strategic bang, announcing a potentially $1.2 billion licensing deal with China's Suzhou Zelgen Biopharmaceuticals for exclusive rights to develop and commercialize alveltamig (ZG-006) outside of Greater China. The New Year's Eve agreement represents one of the largest T-cell engager